DOM-PRAVASTATIN 10 MG
PRAVASTATIN SODIUM : 10 MG · DIN 02249723 · DOMINION PHARMACAL
Health Canada status: CANCELLED POST MARKET
What is DOM-PRAVASTATIN?
DOM-PRAVASTATIN 10 MG contains PRAVASTATIN SODIUM : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02249723, held by DOMINION PHARMACAL, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 09-May-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DOM-PRAVASTATIN used for?
Dom-PRAVASTATIN is indicated as an adjunct to diet for the reduction of elevated Total and Low Density Lipoprotein Cholesterol (LDL-C) levels in patients with primary hypercholesterolemia (Types IIa and IIb), when the response to diet and other non-pharmacologic measures alone has been inadequate. In hypercholesterolemic patients without clinically evident coronary heart disease, Dom-PRAVASTATIN is indicated to reduce the risk of myocardial infarction, myocardial revascularization procedures, and total mortality by reducing cardiovascular deaths. In patients with total cholesterol in the normal to moderately elevated range who have clinically evident coronary heart disease, Dom-PRAVASTATIN is indicated to reduce the risk of total mortality, death due to coronary heart disease, myocardial infarction, myocardial revascularization procedures, stroke and transient ischemic attack (TIA), and total hospitalization. It was also found to reduce the rate of progression of atherosclerosis in patients with coronary heart disease.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02249723 |
|---|---|
| Brand name | DOM-PRAVASTATIN |
| Generic / active ingredient | PRAVASTATIN SODIUM : 10 MG |
| Manufacturer | DOMINION PHARMACAL |
| Strength | 10 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C10AA03 PRAVASTATIN |
| AHFS class | 24:06.08 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 09-May-2025 |
| Original market date | 2004-05-12 00:00:00 |
How is it stored and handled?
null
How is it supplied?
null
What can be used instead?
Other Canadian products sharing ATC code C10AA03 PRAVASTATIN. 51 of 126 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-PRAVASTATIN | 10 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02440644 |
| ACH-PRAVASTATIN | 20 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02440652 |
| ACH-PRAVASTATIN | 40 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02440660 |
| AG-PRAVASTATIN | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02476142 |
| AG-PRAVASTATIN | 20 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02476150 |
| AG-PRAVASTATIN | 40 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02476169 |
| APO-PRAVASTATIN | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02243506 |
| APO-PRAVASTATIN | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02243507 |
| APO-PRAVASTATIN | 40 MG | TABLET | APOTEX INC | MARKETED | DIN 02243508 |
| AURO-PRAVASTATIN | 10 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02458977 |
Who else supplies PRAVASTATIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PRAVASTATIN appears in 291 registered pack listings across 8 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.